We bring you the latest news from the healthcare about the health care in the United Kingdom.

dinsdag 11 september 2018

The Lancet: [Comment] Maternal hormonal contraception and childhood leukaemia

[Comment] Maternal hormonal contraception and childhood leukaemia
The treatment of childhood leukaemias has improved in recent years because of additional knowledge of acute leukaemia genetic subtypes, pathogenesis mechanisms, prognosis prediction, and targeted therapies. The natural history of this disorder is determined by several interacting factors, including exposure to risk factors, susceptibility, and cell biology origin. Therefore, data generated by population-based registries are indispensable for aetiology research, health-care planning, and treatment of childhood leukaemias.
Read more

[News] CNS efficacy of osimertinib in EGFR-mutated advanced NSCLC
Osimertinib could be more efficacious than standard EGFR tyrosine kinase inhibitors (TKIs) at reducing the risk of CNS progression in patients with untreated EGFR-mutated advanced non-small-cell lung cancer (NSCLC), according to a new study.
Read more

[News] Preliminary activity of capmatinib with gefitinib in NSCLC
Results from a phase 1b/2 study show that a combination of the MET inhibitor capmatinib and the EGFR inhibitor gefitinib is tolerable and shows preliminary activity in patients with EGFR-mutated, MET-dysregulated (amplified or overexpressed) non-small-cell lung cancer (NSCLC).
Read more

[Articles] Effect of apalutamide on health-related quality of life in patients with non-metastatic castration-resistant prostate cancer: an analysis of the SPARTAN randomised, placebo-controlled, phase 3 trial
In asymptomatic men with high-risk non-metastatic castration-resistant prostate cancer, HRQOL was maintained after initiation of apalutamide treatment. Considered with findings from SPARTAN, patients who received apalutamide had longer metastasis-free survival and longer time to symptomatic progression than did those who received placebo, while preserving HRQOL.
Read more

[Comment] Camrelizumab for nasopharyngeal carcinoma: a new hope?
Wenfeng Fang and colleagues1 report on two phase 1 studies of the programmed cell death-1 (PD-1) inhibitor, camrelizumab (SHR-1210), as a treatment for patients with recurrent or metastatic nasopharyngeal carcinoma. The first trial tested camrelizumab monotherapy in 93 patients who received at least one previous line of treatment for recurrent or metastatic nasopharyngeal carcinoma. The second trial tested camrelizumab in combination with gemcitabine and cisplatin as a first-line treatment in 23 treatment-naive patients with the same diagnosis.
Read more